Antoni Ribas, M.D., Ph.D.
Positions & Affiliations:
Professor of Medicine (tenured)
Professor of Surgery
Professor of Molecular and Medical Pharmacology
Director, Tumor Immunology Program – JCCC
American Society of Clinical Oncology – ASCO
American Association for Cancer Research – AACR (President 2020)
Antoni Ribas, M.D., Ph.D., is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered T-cells, PD-1 blockade therapy and BRAF targeted therapies. His National Cancer Institute (NCI), State of California and foundation-supported laboratory develops models of disease to test new therapeutic options, studies mechanisms of action of treatments in patients and the molecular mechanisms of therapy resistance. He has been instrumental in the clinical development of several agents approved by the FDA, including pembrolizumab (Keytruda), vemurafenib (Zelboraf), cobimetinib (Cotellic), dabrafenib (Tafinlar) and trametinib (Mekinist).
University of Barcelona, Spain – M.D., 1990
Vail d’Hebron Hospital, Spain – Residency
Autonomous U. of Barcelona, Spain – Ph.D.
UCLA, Los Angeles, CA, United States – Postdoc/Fellow